Myocardial fibrosis and right ventricular function of heterotopically transplanted hearts in rats treated with cyclosporin
Language English Country Netherlands Media print
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
8974065
DOI
10.1007/bf00408666
Knihovny.cz E-resources
- MeSH
- Cyclosporine therapeutic use MeSH
- Endomyocardial Fibrosis physiopathology MeSH
- Hydroxyproline metabolism MeSH
- Blood Pressure MeSH
- Rats MeSH
- Rats, Wistar MeSH
- Heart physiopathology MeSH
- Heart Ventricles physiopathology MeSH
- Heart-Lung Transplantation * MeSH
- Animals MeSH
- Check Tag
- Rats MeSH
- Male MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Cyclosporine MeSH
- Hydroxyproline MeSH
The aim was to determine whether treatment of rats with cyclosporin A (CsA) leads to deleterious side effects on heterotopically iso- or allotransplanted hearts when compared with recipient native in situ hearts. Four experimental groups were employed: inbred (Lewis) rats receiving either no immunosuppression or CsA at a dose of 15 mg.kg-1 per day for 7 days after surgery, and outbred (Wistar) rats receiving CsA at the same daily dose for either 7 or 21 days. One month following surgery, the mass of all transplanted hearts decreased and resulting atrophy was associated with relative myocardial fibrosis. Treatment with CsA significantly increased the concentration and content of collagen in the right and left ventricles of all transplanted and recipient hearts. No appreciable difference was observed between corresponding hearts of inbred and outbred groups receiving the identical dose of CsA, and between hearts in outbred groups treated for either 7 or 21 days. No signs of right ventricular mechanical dysfunction, as assessed on the isolated perfused "working' preparation, were observed after CsA treatment in both transplanted and recipient hearts. The maximal steady state developed pressure (RVDevP) and the rate of its development [(+dP/dt)max] were slightly higher in transplants than in the corresponding recipients, and in CsA-treated versus untreated hearts, while the index of contractile state [(+dP/dt)/P] was similar in all groups. The data suggest that treatment of rats with CsA can induce a similar degree of fibrosis both in heterotopic cardiac transplants and in recipient native hearts without impairment of their contractile performance.
See more in PubMed
Transplantation. 1993 Oct;56(4):885-91 PubMed
Circulation. 1993 Apr;87(4):1368-77 PubMed
Cardiovasc Clin. 1990;20(2):179-88 PubMed
Int J Cardiol. 1991 Apr;31(1):15-22 PubMed
J Heart Transplant. 1988 Mar-Apr;7(2):145-51 PubMed
J Mol Cell Cardiol. 1994 Mar;26(3):279-92 PubMed
J Pharmacol Exp Ther. 1986 Oct;239(1):229-35 PubMed
Cardiovasc Res. 1993 Mar;27(3):341-8 PubMed
Transplant Proc. 1993 Aug;25(4):2735-7 PubMed
Am J Pathol. 1970 May;59(2):279-98 PubMed
Cardiovasc Res. 1993 Feb;27(2):172-5 PubMed
Cardiovasc Res. 1993 Jul;27(7):1244-7 PubMed
Eur J Pharmacol. 1993 Dec 1;248(4):341-4 PubMed
Hypertension. 1991 Oct;18(4):458-66 PubMed
J Pharmacol Exp Ther. 1991 Nov;259(2):905-15 PubMed
J Heart Lung Transplant. 1993 Mar-Apr;12 (2):199-204 PubMed
Mol Cell Biochem. 1993 Dec 22;129(2):121-31 PubMed
J Heart Transplant. 1987 May-Jun;6(3):180-5 PubMed
Transplantation. 1994 May 15;57(9):1382-8 PubMed
Kidney Int. 1994 Apr;45(4):1203-10 PubMed
J Pharm Pharmacol. 1990 Jul;42(7):525-7 PubMed
Circulation. 1989 Jan;79(1):66-75 PubMed
Hum Pathol. 1990 Apr;21(4):424-8 PubMed
J Hypertens Suppl. 1993 Dec;11(5):S122-3 PubMed
N Engl J Med. 1989 Dec 21;321(25):1725-38 PubMed
Circ Res. 1989 Oct;65(4):934-45 PubMed
Pflugers Arch. 1991 Sep;419(2):121-6 PubMed
Transplantation. 1988 Aug;46(2):285-92 PubMed
Agents Actions. 1984 Oct;15(3-4):306-27 PubMed
Hum Pathol. 1990 Jul;21(7):767-72 PubMed
Transplantation. 1989 Oct;48(4):720-3 PubMed
Cardiovasc Res. 1993 Oct;27(10):1845-54 PubMed
Sixty Years of Heart Research in the Institute of Physiology of the Czech Academy of Sciences